Reveal Transition: Rivaroxaban-Evaluation of Variables Enhancing Antithrombotic Efficacy and Longterm-Outcome in Stabilized Patients With Cardiovascular Disease. A Mechanistic Study in Transition / Stabilized Phase of CAD
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin
- Indications Acute coronary syndromes; Atherosclerosis; Coronary artery disease; Peripheral arterial disorders
- Focus Pharmacodynamics
- Acronyms RevealTrans
- 13 Jul 2022 Planned primary completion date changed from 1 Oct 2021 to 1 May 2020.
- 13 Jul 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 26 Jul 2019 New trial record